Genscript Biotech’s CARVYKTI® Boosts Multiple Myeloma Results

Genscript Biotech (HK:1548) has released an update.

Genscript Biotech’s associate, Legend Biotech, has unveiled promising results from its Phase 3 CARTITUDE-4 study at the 2024 ASH Annual Meeting, showcasing that its CARVYKTI® therapy significantly outperforms standard treatments for multiple myeloma in achieving minimal residual disease negativity. These findings highlight the potential of CARVYKTI® as a leading treatment option, having already gained FDA and European Commission approval. With CARVYKTI® now available in five countries and benefiting over 4,500 patients, the future looks bright for investors eyeing innovation in biotech.

For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.